Telemedical Surveillance and Optimized Treatment of Blood Pressure in Kidney Transplant Recipients
1Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany
Meeting: 2022 American Transplant Congress
Abstract number: 1797
Keywords: Adverse effects, Kidney transplantation, Kidney/pancreas transplantation, Survival
Topic: Clinical Science » Organ Inclusive » 72 - Machine Learning, Artificial Intelligence and Social Media in Transplantation
Session Information
Session Name: Machine Learning, Artificial Intelligence and Social Media in Transplantation
Session Type: Poster Abstract
Date: Tuesday, June 7, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: Patients with chronic kidney disease suffer often from cardiovascular diseases, especially high blood pressure and its complications such as stroke and heart attack. After kidney transplantation, this condition persists and can in addition harm the graft. However, outpatient care surveillance is not ideal to treat high blood pressure sufficiently. mHealth solutions such as remote vital signs seem to have the potential to fill in this gap.
*Methods: To optimize the monitoring of kidney transplant recipients (KTR), the MACCS (Medical Assistant for Chronic Care Solution)-project offers participants an intensified control of vital signs. A telemedicine team reviews daily incoming data and takes action, if necessary. A self-programed telemedicine dashboard visualizes the data. KTR can forward vital signs, well-being, and medication intake protocols via app. Reminder and notifications support adherence. The project began in February 2020 and is ongoing. The concept sticks to General Data Protection Regulation (GDPR) of European Union.
*Results: Between February 2020 and 2021, we cared for 335 KTR and supported them in 290 cases of hypertensive crisis or hypertensive emergency (n=191 (1.2%) systolic BP (SBP) 180 to 228mmHg; n=199 (1.3%) SBP 160 to 179mmHg; n=4 (0.03%) diastolic BP (DBP) >120mmHg; n=323 (2.0%) DBP 100 to 119mmHg; n=4.604 (28.8%) DBP 90 to 99mmHg). In addition, we adjusted the medication plans regard antihypertensive therapy.
*Conclusions: mHealth solutions including remote vital signs and telemedicine personnel for regular evaluation have the potential to optimize blood pressure treatment. Acute onset of hypertensive crisis can be handled sufficiently at home and thus reduce treatment at emergency rooms. Since severe complications of high blood pressure levels manifest after years, long-term results are required to conduct conclusions.
| Participants (N.) | 335 |
| Age (median, range) | 51 (19-87) |
| Female (%) | 35.5 |
| Years since transplant (median, range) | 6 (0-41) |
| Dropouts (%) | 26 (7.76) |
| Return to dialysis or death | 9 |
| Technical issues | 10 |
| Withdrawal | 7 |
| Characteristic | Total | Mean | SD | Max | Min |
| SBP, mmHg | 15973 | 127.62 | 103.7 | 228 | 60 |
| DBP, mmHg | 15973 | 78.51 | 9.97 | 120 | 50 |
| Pulse, bpm | 27481 | 70.37 | 14 | 200 | 40 |
To cite this abstract in AMA style:
Düttmann W, Naik MG, Zukunft B, Osmanodja B, Eleftheriadis G, Ronicke S, Choi M, Bachmann F, Halleck F, Budde K. Telemedical Surveillance and Optimized Treatment of Blood Pressure in Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/telemedical-surveillance-and-optimized-treatment-of-blood-pressure-in-kidney-transplant-recipients/. Accessed May 6, 2025.« Back to 2022 American Transplant Congress